A/Prof Chris Hovens
A/Prof Chris Hovens, BSc, PhD
Director of Scientific Research
A/Prof Hovens is the Director of Scientific Research at the Australian Prostate Cancer Research Centre at Epworth Hospital and Royal Melbourne Hospital. He is a senior scientific investigator on a number of sponsored prostate cancer clinical research programs within the Department of Urology at the Royal Melbourne Hospital and the Department of Surgery at the University of Melbourne. He has served as Chief Scientific Officer and main scientific advisor for two start up, drug development companies he has co-founded, Velacor Therapeutics Pty Ltd and CCH Pharma Pty Ltd.
A/Prof Hovens was awarded a PhD in 1992 for cloning and analysis of the Ryk Receptor Tyrosine Kinase performed at the Ludwig Institute for Cancer Research under the supervision of Drs Andrew Wilks and Ashley Dunn. In 1992, A/Prof Hovens took up a post doctoral position at the Institute for Molecular Biology in Zurich.
In 2001, A/Prof Hovens was promoted to Director of the Prostate Cancer Research Center in the Departments of Urology and Surgery, University of Melbourne. He has also worked on the functional characterization of spread tumour suppressor proteins and made the discovery of a new, tissue-restricted member of the family, Eve-3. His recent work concerns the co-discovery of a small, water soluble inhibitor of the PI3K/Akt pathway which has been extensively characterized in in vitro and in vivo models of prostate and brain cancer.
A/Prof Hovens received $7.5m from the Federal Government with Professor Anthony Costello in 2008 to establish a Research Centre for Prostate Cancer (Australian Prostate Cancer Research Centre at the Epworth Hospital). In 2008, he and Professor Costello have also received a project grant ($460 000) from the Prostate Cancer Foundation of Australia for their Circulating Cells as Biomarkers for Prostate Cancer study. He has more than 55 peer-reviewed articles and 2 Book Chapters.